Sirnaomics, Inc. has announced that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin" (US 8,735,567 B2, PCT/US2008/012498).
This USPTO issuance, combined with a similar success for a Chinese patent (ZL 200880124132.8) provides a solid foundation and protection for the company's leading siRNA therapeutic project under development both in the USA and in China.
Sirnaomics is a leading biopharmaceutical company active in discovery and development of siRNA therapeutics. The company's mission is to advance siRNA therapeutics by using its proprietary multi-targeted siRNA design and screening together with proprietary nanoparticle-mediated siRNA delivery vehicles. Through in-house efforts and collaborations, Sirnaomics has developed three generations of peptide nanoparticle-based siRNA delivery systems: self-assembled nanoparticles, ligand-directed nanoparticles, and infrared-activated nanoparticles.
Each formulation is adapted to different therapeutic applications. Based on its proprietary technologies, Sirnaomics has developed a rich pipeline of siRNA therapeutic candidates, including STP705 for prevention and treatment of skin hypertrophic scars, STP702 for prophylaxis and therapeutics against influenza infection, and STP523 for treatment of solid tumor.
The recent issued patent plus two additional issued patents, "Compositions for Treating Respiratory Viral Infections and Their Use" (US 8,691,781 B2, PCT/US2005/040048) and "Compositions and Methods Using siRNA Molecules for Treatment of Gliomas" (US 8,541,568 B2, PCT/US2009/003196), strengthen Sirnaomics' intellectual property portfolio covering the company's technology and siRNA therapeutics products.
"Intellectual property landscape for RNAi therapeutics has been emerging very differently today comparing 7-8 years ago. With three issued patents and a number of patent applications plus those licensed in IPs, Sirnaomics is well positioned for our siRNA therapeutic product development and technology advancement," said the Founder and President of the company, Dr. Patrick Y. Lu. "We will continue building our proprietary technology while pushing forward the leading siRNA therapeutic programs into clinics both in US and China." Dr. Lu further emphasized, "Sirnaomics' dual-targeted siRNA drug design and peptide nanoparticle delivery platform allow a great chance of success of our leading siRNA therapeutic candidates."
"Sirnaomics patent portfolio and product pipeline represent a clear leading position among privately held companies in the field," commented the recently appointed new CEO, Dr. Marc Lemaitre. "The ongoing efforts to start clinical studies with the leading siRNA therapeutic candidate STP705 both in the USA and in China are creating tremendous value for the company. We expect successful clinical studies for the leading compound and following candidates to further validate and reinforce the value of the company's intellectual property."
Dr. Lemaitre added, "More importantly, these therapeutic candidates are addressing unmet clinical needs with broad market potential."